公开(公告)号：US20150368612A1

公开(公告)日：2015-12-24

申请号：US14719968

申请日：2015-05-22

Applicant: Baylor Research Institute

Inventor： Anna Karolina Palucka ,  Jacques F. Banchereau ,  Lee Roberts

IPC: C12N5/0784 ,  A61N5/10 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06

CPC classification number: C12N5/0639 ,  A61K31/337 ,  A61K31/675 ,  A61K31/704 ,  A61K35/15 ,  A61K38/2006 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/545 ,  A61K2039/6006 ,  C12N2501/22 ,  C12N2501/2304 ,  A61K2300/00

Abstract: Disclosed are compositions and methods for treatment of breast cancer. Disclosed methods and compositions include dendritic cells loaded with cyclin B1 and WT-1 peptide antigens for immunotherapy. These dendritic cell vaccines are administered alone or in combination with other cancer therapies to improve outcomes. Disclosed methods also involve the use of therapeutic agents, such as anakinra, that block the IL-1 inflammation pathway. These agents are used in combination with chemotherapy and/or immunotherapy in treating breast cancer.

Abstract translation: 公开了用于治疗乳腺癌的组合物和方法。 公开的方法和组合物包括负载有用于免疫治疗的细胞周期蛋白B1和WT-1肽抗原的树突状细胞。 这些树突细胞疫苗单独施用或与其他癌症疗法组合施用以改善结果。 所公开的方法还涉及使用阻断IL-1炎症途径的治疗剂，例如阿那白拉。 这些药剂与化疗和/或免疫治疗联合用于治疗乳腺癌。

公开(公告)号：US09102730B2

公开(公告)日：2015-08-11

申请号：US13872793

申请日：2013-04-29

Applicant: Baylor Research Institute

Inventor： Gerard Zurawski ,  Jacques F. Banchereau ,  Eynav Klechevsky ,  Sandra Zurawski ,  Anne-Laure Flamar

IPC: A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K39/395 ,  C07K16/46 ,  C07K16/28 ,  B82Y5/00 ,  A61K47/48 ,  C12N5/0784 ,  A61K39/02 ,  A61K39/00

CPC classification number: C07K16/2851 ,  A61K39/02 ,  A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K47/6897 ,  A61K47/6901 ,  A61K2039/505 ,  A61K2039/6056 ,  B82Y5/00 ,  C12N5/0639 ,  C12N2760/16134

Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Abstract translation: 本发明包括使用形成抗体 - 抗原复合物的抗原附着的DCIR特异性抗体或其片段增加抗原呈递的有效性的组合物和方法，其中所述抗原由具有抗体 - 抗原复合物的树突状细胞加工和呈递， 与抗体 - 抗原复合物接触。

公开(公告)号：US20150105585A1

公开(公告)日：2015-04-16

申请号：US14523810

申请日：2014-10-24

Applicant: Baylor Research Institute

Inventor： Charles R. Roe

IPC: A61K31/194 ,  A61K31/19

CPC classification number: A61K31/20 ,  A61K31/19 ,  A61K31/194 ,  A61K31/23

Abstract: A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.

Abstract translation: 已经发现治疗需要治疗心脏病症的患者的方法包括向患者施用七碳脂肪酸化合物或其衍生物，其中所述化合物或其衍生物能够容易地进入线粒体而没有特殊的转运酶。 已经发现适合于治疗心脏或外科手术患者心脏组织的膳食制剂包括七碳脂肪酸链，其中七碳脂肪酸链的特征在于通过运输机制横向内线粒体膜的能力 其不需要肉碱棕榈酰转移酶I，肉碱棕榈酰转移酶II或肉碱/酰基肉毒碱转位酶，并且具有进行线粒体和氧化的能力，并且其中所述化合物选自正庚酸或其衍生物，甘油三酯 包括正庚酸或其衍生物，和三庚醇或其衍生物。

公开(公告)号：US20140322214A1

公开(公告)日：2014-10-30

申请号：US14264967

申请日：2014-04-29

Applicant: Baylor Research Institute

Inventor： Jacques F. Banchereau ,  SangKon Oh ,  Gerard Zurawski ,  Sandra Zurawski ,  Ling Ni

IPC: C07K16/28 ,  C12N9/24 ,  C07K16/10

CPC classification number: C07K16/2851 ,  A61K39/395 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K16/1018 ,  C07K2317/24 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2319/00 ,  C12N5/0639 ,  C12N9/2402 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/50 ,  C12N2501/998

Abstract: The present invention includes compositions and methods for binding Dectin-1 on immune cells with anti-Dectin-1-specific antibodies or fragment thereof capable of activating the immune cells.

Abstract translation: 本发明包括用能够激活免疫细胞的抗Dectin-1特异性抗体或其片段将Dectin-1与免疫细胞结合的组合物和方法。

公开(公告)号：US20140030264A1

公开(公告)日：2014-01-30

申请号：US13863131

申请日：2013-04-15

Applicant: Baylor Research Institute

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  Eynav Klechevsky ,  SangKon Oh

IPC: C07K16/28 ,  C07K14/005 ,  C07K14/47

CPC classification number: C07K16/2896 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/55561 ,  A61K2039/6056 ,  C07K14/005 ,  C07K14/4748 ,  C07K16/2851 ,  C07K2319/00 ,  C07K2319/33 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2760/16134

Abstract: The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.

Abstract translation: 本发明包括分离的抗兰格林疫苗，分离的抗 - 兰格林抗体的羧基末端制备和使用分离的抗 - 兰格林抗体或其结合片段和一种或多种抗原肽的方法，其中当两种或多种抗原 存在肽，肽被包含至少一个糖基化位点的一个或多个接头肽隔开。 本发明还包括用于表达抗Langerin抗原递送载体的分离载体及其制备和用途。

公开(公告)号：US20130295120A1

公开(公告)日：2013-11-07

申请号：US13872793

申请日：2013-04-29

Applicant: Baylor Research Institute

Inventor： Gerard Zurawski ,  Jacques F. Banchereau ,  Eynav Klechevsky ,  Sandra Zurawski ,  Anne-Laure Flamar

IPC: C07K16/28 ,  C12N5/0784

CPC classification number: C07K16/2851 ,  A61K39/02 ,  A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K47/6897 ,  A61K47/6901 ,  A61K2039/505 ,  A61K2039/6056 ,  B82Y5/00 ,  C12N5/0639 ,  C12N2760/16134

Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Abstract translation: 本发明包括使用形成抗体 - 抗原复合物的抗原附着的DCIR特异性抗体或其片段增加抗原呈递的有效性的组合物和方法，其中所述抗原由具有抗体 - 抗原复合物的树突状细胞加工和呈递， 与抗体 - 抗原复合物接触。